The anti-PD-L1/PD-1 immunotherapies, such as pembrolizumab and atezolizumab, have shown significant anti-tumor responses, a favorable safety profile, and prolonged progression-free survival in PD-L1-positive metastatic TNBC [51,52]. Here, PDCD1 is linked to neoplasm.